Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome: Diagnostic and Laboratory Approach
DOI:
https://doi.org/10.24293/ijcpml.v29i1.2029Keywords:
NAFLD, metabolic syndrome, early diagnosticAbstract
Both Non-Alcoholic Fatty Liver Disease (NAFLD) and metabolic syndrome are health problems worldwide. Various studies suggest that NAFLD and metabolic syndrome have a two-way relationship. Metabolic syndrome can be preceded by NAFLD and NAFLD can be a manifestation of the metabolic syndrome. Because of the relationship between the two, the diagnosis and management of NAFLD and metabolic syndrome are important to prevent complications such as cardiovascular disease, liver cirrhosis, and malignancy. The diagnosis of metabolic syndrome can be made based on various diagnostic criteria determined by several health organizations, such as WHO, IDF, and NCEP-ATP. Since NAFLD is asymptomatic until advanced disease, many patients are only identified at advanced stages. Liver biopsy is currently the gold standard for diagnosing NASH, which is a type of NAFLD. This procedure is invasive, and many studies are currently looking for and assessing non-invasive markers for NAFLD and metabolic syndrome. Laboratory as diagnostic support plays an important role in the diagnosis of NAFLD and metabolic syndrome. Non-invasive laboratory tests with high sensitivity and specificity are expected to contribute to the early diagnosis of NAFLD and metabolic syndrome. Various laboratory parameters have been developed to support the diagnosis of NAFLD and metabolic syndrome.Downloads
References
Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The prevalence of metabolic syndrome in non-alcoholic fatty liver disease; A population-based study. Middle East J Dig Dis, [Internet]. 2016; 8(2): 131-7. Available from: http://dx.doi.org/10.15171 /mejdd.2016.18 (accessed July 10, 2022).
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med, 2017; 15(1): 1-6.
Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Non-alcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis, [Internet]. 2015; 47(3): 181-90. Available from: http://dx.doi.org/
1016/j.dld.2014.09.020 (accessed July 12, 2022).
Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: An update on diagnosis. Clujul Med, 2018; 91(2): 147-50.
Godoy?Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr, 2020; 12: 60.
Sigit FS, Tahapary DL, Trompet S, Sartono E, Willems Van Dijk K, et al. The prevalence of metabolic
syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: A cross-sectional analysis of two population-based studies. Diabetol Metab Syndr, [Internet]. 2020; 12(1):1-11. Available from: https://doi.org/10.1186/s13098-019-0503-1 (accessed July 8, 2022).
Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: An update on diagnostic criteria, pathogenesis, and genetic links. Hormones, 2018; 17(3): 299-313.
Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Mol Sci, 2016; 17(3): 367.
Jagannathan R, Neves JS, Dorcely B, Chung ST, Tamura K, et al. The oral glucose tolerance test: 100 years later. Diabetes, Metab Syndr Obes Targets Ther, 2020; 13: 3787-805.
World Health Organization & International Diabetes Federation. Definition and diagnosis of diabetes
mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation. [Internet]. World Health
Organization, 2006; 1-50. Available from: https://apps. who.int/iris/handle/10665/43588 (accessed July 20, 2022).
Horáková D, Å tÄ›pánek L, Å tÄ›pánek L, Pastucha D, Janoutová J, et al. What are the real associations of Homeostasis Model Assessment (HOMA) with body mass index and age?. Endokrynol Pol, 2022; 73(4): 736-42.
Arellano-Ruiz P, García-Hermoso A, Cavero-Redondo I, Pozuelo-Carrascosa D, Martínez-Vizcaíno V,
Solera-Martinez M. Homeostasis model assessment cut-off points related to metabolic syndrome in
children and adolescents: a systematic review and meta-analysis. Eur J Pediatr, 2019; 178(12): 1813-22.
Fiorentino TV, Marini MA, Succurro E, Andreozzi F, Sesti G. Relationships of surrogate indexes of insulin resistance with insulin sensitivity assessed by euglycemic hyperinsulinemic clamp and subclinical
vascular damage. BMJ Open Diabetes Res Care, 2019; 7(1): e000911.
Muniyappa R, Madan R. Assessing Insulin sensitivity and resistance in humans [Internet]. Feingold K,
Anawalt B, Boyce A, editors. Endotext. South Dartmouth (MA): MDText.com, Inc; 2021. Available
from: https://www.ncbi.nlm.nih.gov/books/NBK278954/ (accessed July 5, 2022).
Mirzaalian Y, Nourian M, Gholamalizadeh M, Doaei S, Hatami M, et al. The association of quantitative insulin sensitivity indices (HOMA-IR and QUICKI) with anthropometric and cardiometabolic indicators in
adolescents. Arch Med Sci - Atheroscler Dis, 2019; 4(1): 32-7.
Karanchi H, K. W. Hypertriglyceridemia - StatPearls - NCBI bookshelf [Internet]. 2017. Available from: https://www. ncbi.nlm.nih.gov/books/NBK459368/?report=reader(accessed July 5, 2022).
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - What is it and how should it be managed?. Eur J Prev Cardiol, 2019; 26(2_suppl): 33-46.
Rahmayani R, Aman AK, Safril S. The association of insulin resistance and lipid profile ratio in metabolic syndrome. Indones J Clin Pathol Med Lab [Internet]. 2019; 25(1): 21-5. Available from: https://
indonesianjournalofclinicalpathology.org/index.php/patologi/article/view/1484/1055 (accessed August
, 2022).
Majerczyk M, Kocełak P, Choręza P, Arabzada H, Owczarek AJ, et al. Components of metabolic
syndrome in relation to plasma levels of retinol binding protein 4 (RBP4) in a cohort of people aged 65
years and older. J Endocrinol Invest, [Internet]. 2018; 41(10): 1211-9. Available from: https://doi.org/
1007/s40618-018-0856-6 (accessed September 10, 2022).
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab, 2015; 19(5): 597-601.
Feng G, Feng L, Zhao Y. Association between ratio of γ-glutamyl transpeptidase to high-density
lipoprotein cholesterol and prevalence of non-alcoholic fatty liver disease and metabolic syndrome: A cross-sectional study. Ann Transl Med, 2020; 8(10): 634-634.
Hadizadeh F, Faghihimani E, Adibi P. Non-alcoholic fatty liver disease: Diagnostic biomarkers. World J
Gastrointest Pathophysiol, 2017; 8(2): 11-26.
Huang X, Xu M, Chen Y, Peng K, Huang Y, et al. Validation of the fatty liver index for non-alcoholic fatty liver disease in middle-aged and elderly Chinese. Med (United States), 2015; 94(40): 1-7.
Liu Z, Liang S, Que S, Zhou L, Zheng S, Mardinoglu A. Meta-analysis of adiponectin as a biomarker for the detection of metabolic syndrome. Front Physiol, 2018. Available from: https://www.frontiersin.org/
articles/10.3389/fphys.2018.01238/full (accessed September 10, 2022).
Gudowska M, Cylwik B, Chrostek L. The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis. Acta Biochim Pol, 2017; 64(3): 451-7.
Chang YH, Lin HC, Hwu DW, Chang DM, Lin KC, Lee YJ. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Ann Clin Biochem, 2019;
(1): 141-7.
Qian L, Zhang L, Wu L, Zhang J, Fang Q, et al. Elevated serum level of cytokeratin 18 M65ED is an
independent indicator of cardiometabolic disorders. J Diabetes Res, 2020; 2020: 5198359.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
